Furthermore, the in vitro drug-sensitivity in cell lines would suggest that PGC-1alpha and GAPDH/MT-CO1 levels could be used to predict patient response to treatments based on targeting glucose metabolism on lung cancer. Here, PPARGC1A is linked to lung cancer.